Liquid biopsy for monitoring medulloblastoma
2022

Liquid Biopsy for Monitoring Medulloblastoma

publication Evidence: moderate

Author Information

Author(s): Eibl Robert H., Schneemann Markus

Primary Institution: Hospitals of Schaffhausen, Switzerland

Hypothesis

Can liquid biopsy techniques improve the monitoring and management of medulloblastoma?

Conclusion

Liquid biopsy, particularly using cerebrospinal fluid, shows promise for better monitoring and management of medulloblastoma compared to traditional methods.

Supporting Evidence

  • Liquid biopsy can detect tumor-derived DNA in cerebrospinal fluid more effectively than in blood.
  • ctDNA levels can indicate tumor progression or response to treatment.
  • CSF is a preferred source for ctDNA due to its higher sensitivity for brain tumors.

Takeaway

Doctors can use a special blood test called liquid biopsy to check for brain tumors in kids without needing to do surgery. This helps them decide the best treatment without hurting the kids more than necessary.

Methodology

This review summarizes various methodologies of liquid biopsy and their application in monitoring medulloblastoma.

Limitations

Challenges include low amounts of ctDNA in medulloblastomas and the need for more clinical studies to establish standards.

Digital Object Identifier (DOI)

10.20517/evcna.2022.36

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication